The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.
The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, to break the patents of drugs that were developed with federal funds but are not widely accessible to the public. For the first time, officials can now factor in a medication’s price — a change that could have big implications for drugmakers depending on how the government uses the powers.
“When drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard said during a call with reporters Wednesday.
I wish media would give credit to the organization leaders responsible for these types of moves rather than crediting a homogeneous “Biden administration.” The fact is that the administration does deserve credit for employing a number of “progressive” (read: competent) administrators, but those departments compose a progressive wing of the administration that is not on par with some of the overall administration’s more centrist leanings.
Personnel are policy, something that the Biden administration has proved again and again since the 2020 election. Biden himself is a kind of empty vessel into which different wings of the Democratic party pour their will, yielding a strange brew of appointments both great and terrible.
